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The complement system of innate immunity is important in regulating humoral immunity largely through the
complement receptor CR2, which forms a coreceptor on B cells during antigen-induced activation. However,
CR2 also retains antigens on follicular dendritic cells (FDCs). Display of antigen on FDCs is critical for clonal
selection and affinity maturation of activated B cells. This review will discuss the role of complement in
adaptive immunity in general with a focus on the interplay between CR2-associated antigen on B cells
with CR2 expressed on FDCs. This latter interaction provides an opportunity for memory B cells to sample
antigen over prolonged periods. The cocrystal structure of CR2 with its ligand C3d provides insight
into how the complement system regulates access of antigen by B cells with implications for therapeutic
manipulations to modulate aberrant B cell responses in the case of autoimmunity.Introduction
The paradigm first suggested by Janeway over two decades
ago, that innate immunity was essential for regulating adaptive
responses, focused attention on how pathogens were recog-
nized and taken up by dendritic cells for presentation to
T cells (Janeway, 1989). Later, Fearon and Locksley (1996)
proposed that B cells were equally reliant on innate recognition
for acquisition of cognate antigens and that the complement
system played a critical role in signaling B cell activation.
More recently, in vivo imaging studies tracking B cell capture
of lymph-borne antigens in real time have again provided
a major shift in our understanding of how the innate system
regulates humoral immunity. For example, specialized macro-
phages lining the subcapsular sinus of peripheral lymph nodes
(pLNs) have been shown to capture both particulate (Carrasco
and Batista, 2007; Junt et al., 2007) and soluble immune
complexes via complement receptors (Phan et al., 2007) and
display them to cognate B cells in the underlying B cell follicles.
Alternatively, small protein antigens have been found to drain
directly from the subcapsular sinus into the follicles through
collagen-rich conduits enveloped by fibroblast reticular cells
(FRCs) (Baje´noff and Germain, 2009; Roozendaal et al., 2009).
Although these pathways provide insight into how memory B
cells can directly sample antigen within lymph nodes, they leave
open the question of how B cell antigens are retained and
sampled over longer periods. An important clue to answering
this question has come from the recent report by Cyster and
colleagues as they made the striking observation that naive B
cells are highly efficient at taking up and transporting immune
complexes bound to complement receptor (CR2) to B cell
follicles within pLNs, where they are transferred to follicular
dendritic cells (FDCs) for long-term retention (Phan et al.,
2009). These exciting new findings combined with the recent
solving of the cocrystal structure of CR2 in complex with the
complement fragment C3d (van den Elsen and Isenman, 2011)
suggest a new perspective in how the complement system
regulates access of antigen by B cells. In this review, we will
discuss these recent findings and how they might lead topossible therapies to ‘‘tune-down’’ aberrant B cell responses
in the case of autoimmunity.
Complement Receptor CR2 in Humoral Immunity
Starting from an initial observation 40 years ago that depleting
complement component C3 from the serum of an experimental
animal results in an impaired antibody response to T cell-depen-
dent antigen (Pepys, 1972), there has been a substantial body of
research directed at understanding the molecular basis for this
complement link to the regulation of the adaptive humoral
immune response. The various milestones in this quest have
been documented in several past reviews (Carroll, 2000; Carroll,
2004; Nielsen and Leslie, 2002; Rickert, 2005; Roozendaal and
Carroll, 2007). It is now clear that at the heart of complement’s
effect on adaptive humoral immunity is the interaction between
complement receptor 2 (CR2, CD21), which is primarily present
on B cells and follicular dendritic cells (FDCs) in humans and
mice, with an antigen-bound fragment of C3 in which the C3d
moiety is fully accessible (Figure 1).
Before dealing with the models that have emerged for the
role of the CR2:C3d interaction in adaptive immunity, it is
important to appreciate how the antigen gets ‘‘tagged’’ with
the appropriate C3 split product via the classical or lectin
complement pathways. These processes are dependent upon
antigen recognition by an activator of the classical or lectin path-
ways, such as natural repertoire IgM antibody (Boes et al., 1998)
(Fischer et al., 1996), C-type lectins such as SIGN-R1 (Kang
et al., 2006), or mannan binding lectin (Degn et al., 2007; Takaha-
shi et al., 2008). When associated with antigen, IgM and SIGN-
R1 engage the C1q subcomponent of the proenzyme form of
C1 and this results in C1 activation. The now activated form of
the C1s subcomponent of C1 cleaves the next component
of the classical pathway, C4, into C4a and C4b, with a portion
of the C4b becoming covalently bound to the antigen (see
below). There it binds C2, which in turn is also cleaved by
activated C1s into the active serine protease fragment C2a.
The resulting antigen-attached enzyme, C4b2a, is the classical
pathway C3 convertase and it cleaves many molecules of C3Immunity 37, August 24, 2012 ª2012 Elsevier Inc. 199
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Figure 1. Structure-Based Cartoon Depiction of the Processes Involved in the Covalent Tagging of Antigen with C3b and Its Subsequent
Degradation to to the Equivalent CR2 Ligands iC3b, C3dg, and C3d
In native C3, the intramolecular thioester bond of the TED is buried at an interface and is thus denoted in gray. After proteolytic removal of the C3a activation
fragment by C3 convertase, which would be present on the antigen surface, a massive conformational change ensues in the C3b fragment. The activated
thioester carbonyl becomes exposed and can react with a hydroxyl group on the antigen surface (gray, shaded box), thereby forming a covalent ester linkage.
Whereas the CR2 binding surface of the C3dmoiety is largely obstructed in C3b, it becomes accessible as a result of the conformational changes accompanying
removal of the small C3f peptide of the CUB (for complement C1r and C1s, Uegf, and bonemorphogenic protein 1) domain by factor I (in concert with cofactor FH)
that generates iC3b. An additional cleavage of the CUB domain by FI (this time requiring CR1 [CD35] as the cofactor) releasesC3c and leaves C3dg still covalently
bound to the antigen. Further proteolytic trimming of C3dg can yield the C3d limit fragment. These cartoons, although greatly simplified to depict only the most
relevant domains as individual entities, are based on the crystal structures of native C3 and C3b (Janssen et al., 2006) and EM images of iC3b (Alcorlo et al., 2011;
Nishida et al., 2006). The relative binding affinities of the antigen-bound C3 split products are indicated.
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C3b molecules become covalently bound to the antigen. In the
case of antigen recognition by mannan binding lectin (MBL),
the MBL-associated serine proteases (MASPs) become acti-
vated, and like C1s, activated MASP2 can cleave C4 and C2,
thus yielding an antigen-bound C3 convertase identical to the
one formed by via C1 activation.
As alluded to above, the transfer of the homologous proteins
C3 and C4 from the fluid phase to a target surface involves
a covalent binding reaction. In this transacylation reaction,
a surface nucleophile (hydroxyl group in the case of C3, hydroxyl
and amino groups in the case of human C4) attacks an activated
intramolecular thioester bond formed between the side chains of
cysteine and glutamine residues in the sequence CGEQ located
within the C3d and C4d subfragments of these proteins
(Figure 1). These fragments correspond closely to the respective
structurally defined thioester domains (TEDs). Subsequent
degradation of the antigen-bound C3b to iC3b and C3dg by
the complement regulatory enzyme factor I, and further protease
trimming of C3dg to C3d by a noncomplement protease, will
leave these C3 secondary and tertiary degradation fragments
still covalently attached to the antigen (Figure 1). It is known
from structural work that relative to native C3, the TED is in
a completely different conformational environment in the C3b
fragment, and then again in iC3b (Alcorlo et al., 2011; Janssen
et al., 2006; Nishida et al., 2006). The equivalence of the affinities
for CR2 of the C3 split products iC3b, C3dg, and C3d (Clemenza
and Isenman, 2000; Kalli et al., 1991; Nagar et al., 1998) not only
indicates that C3d contains the CR2 binding site, but also that
the site is equally accessible to CR2 in the precursor degradation
fragments iC3b and C3dg.
There are three distinct modalities that have emerged through
which the interaction of CR2 with antigen opsonized with C3d200 Immunity 37, August 24, 2012 ª2012 Elsevier Inc.affects antibody-mediated adaptive immunity. The first is de-
picted in Figure 2A and occurs at the surface of a B cell. It
involves the coligation of the B cell antigen receptor (BCR) to
CR2, during which both the primary receptor, i.e., the BCR,
and the coreceptor, i.e., CR2, are each individually associated
with cell signaling platforms. Coligation results in augmented
signaling as a result of the redistribution of the entire receptor-
coreceptor complex to lipid rafts (Cherukuri et al., 2001). In the
presence of large doses of antigen, there is sufficient crosslink-
ing of the BCR complex so that the signaling provided via the
associated Iga;Igb platform is sufficient to induce activation
and clonal expansion of the antigen-specific B cell, without the
need for complement-mediated coligation of the CR2-CD19-
CD81 coreceptor complex. However, under conditions of
limiting antigen, as would likely be the case that upon initial
encounter with a microbial pathogen, the augmented signaling
occurring as a result of CR2-coreceptor ligation effectively
lowers the threshold dose of antigen required to trigger B cell
clonal expansion.
The second role for the CR2:C3d interaction, as depicted in
Figure 2B, involves FDCs within germinal centers in which, as
a result of trapping C3d-opsonized antigen via CR2, they can
present the antigen to naive or previously antigen-engaged
B cells during the processes of affinity maturation, isotype
switching, and generation of effector and memory B cells
(Fang et al., 1998). These CR2-mediated effects at the surface
of B cells and FDCs are collectively referred to as the ‘‘molecular
adjuvant’’ effects of complement and have been shown in
various experimental systems in which antigen is fused to
multiple copies of C3d to lower the threshold dose of antigen
required for an antibody response in the absence of other
‘‘traditional’’ adjuvants from two to four orders of magnitude
(Barrault et al., 2005; Dempsey et al., 1996; Wang et al.,
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Figure 2. Complement as a Bridge Linking the Innate and Adaptive
Immune Systems: The Molecular Adjuvant Role of Antigen-Linked
C3d
(A) Coligation of the BCR with the CR2-CD19-CD81 complex leads to
augmented signaling when naive B cells first encounter antigen and initiate the
process leading to their clonal expansion. CR2 is composed of 15 CCP
domains, denoted by circles. The white boxed area indicates the key binding
interaction between CR2(CCP1-2) with a C3d TED that is covalently bound
(yellow triangle) to the antigen recognized by the BCR of this particular B cell.
(B) CR2 present on FDCs may also capture C3d-opsonized antigen and
present this antigen to previously primed B cell centrocytes in the germinal
center of the lymph node.
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Review2004a; Wang et al., 2004b). However, these same CR2:C3d-
mediated molecular adjuvant effects, which are beneficial in
the host’s immune response to foreign antigen, can also amplify
an antibody-mediated autoimmune response in the case of
individuals having B cells reactive against self-antigens. This
possibility is discussed in more detail below.
The third modality through which complement interfaces with
adaptive humoral immunity involves the delivery of antigen to
FDCs and this topic will be dealt with separately in a subsequent
section.
Complement C3 in T Cell Immunity
Although the focus of this review is primarily on B cell immunity,
complement also participates in activation of T cells and several
excellent reviews have reported on the topic (Kemper and
Atkinson, 2007b; Dunkelberger and Song, 2010; Sacks and
Zhou, 2012). Using a murine model of influenza infection, Kopf
and colleagues first identified an essential role for complementC3 in the T cell response to the virus. Mice deficient in C3 failed
to clear the virus efficiently relative to WT controls and their
adaptive response was characterized by an impairment in both
the B cell and T cell compartment. Examination of the CD4+
and CD8+ T cell response at early time points showed a marked
decrease in T cell proliferation and release of cytokines such as
interferon gamma. Later studies confirmed the sensitivity of
C3-deficient mice to influenza infection, showing a high inci-
dence of mortality that correlates with impaired B cell memory
(Fernandez Gonzalez et al., 2008). Interestingly, mice deficient
in CD21 and CD35 (Cr2/) appear to respond to infectious virus
similar to WT controls, suggesting the T cell defect is not medi-
ated through this pathway (Kopf et al., 2002). The results are in
agreement with earlier studies by Birgitta Heyman et al., who
found that blockade of CD21 receptors leads to an impaired anti-
body response without limiting the T helper (Th) cells (Gustavs-
son et al., 1995). A possible explanation for the impaired CD4+
Th1 cell response to influenza response is suggested by a recent
study by Pekkarinen et al. (2011). They found that the CD4+ Th1
cell response of C3-deficient mice is reduced relative to WT
controls after immunization with ovalbumin (OVA) in Freund’s
adjuvant and this correlates with a decrease in expression of
interleukin-12 (IL-12) and the Th1 cell lineage transcription factor
T-bet, together with a deviation to Th2 cell response. They
proposed that the defect could be due to either the cytokine
environment or effects of antigen presentation by dendritic cells
(DCs). For example, DCs can produce complement components
locally, which may modulate their cytokine secretion (Sacks and
Zhou, 2012). One relevant pathway is the C5a receptor (C5aR),
which is known to affect Toll-like receptor (TLR) signaling, espe-
cially IL-12, and is linked to Th17 cell and regulatory T (Treg) cell
differentiation (Kemper and Atkinson, 2007b; Weaver et al.,
2010). In human T cells, the complement receptor CD46 may
be a major mediator of the effects of C3 (Kemper and Atkinson,
2007a). Earlier studies have shown that crosslinking of CD3 and
CD46 on T cells induces a regulatory T cell phenotype (Kemper
et al., 2003). In their more recent report, the authors show that
activated CD4+ T cells produce ligands for CD46, i.e., C3b and
C4b, that result in IL-10 production and induction of a regulatory
phenotype (Cardone et al., 2010). Thus, the CD46 receptor that
was first identified as a regulator of C3b and C4b to protect
host cells from activated complement has potent effects on
the cytokine production of T cells and a strong influence on the
overall T helper cell phenotype.
The CR2:C3d Binding Interface
As can be seen in the cartoon depiction in Figure 2, depending
on an alternative splice site used, the extracellular region of
CR2 consists of 15 or 16 complement control protein (CCP)
domains, but the C3d binding site is entirely contained within
the two N-terminal-most CCP domains (Kalli et al., 1991). More-
over, both of these domains must be present to observe C3d
binding (Carel et al., 1990; Lowell et al., 1989). When the struc-
ture of C3d became available (Nagar et al., 1998), it was noted
that one of its prominent features was an acidic residue-lined
depression that was remote from a more convex face of the
molecule harboring the covalent attachment site. On the basis
of its accessible location, the known ionic strength sensitivity
of the CR2:C3d interaction, and the potential for chargeImmunity 37, August 24, 2012 ª2012 Elsevier Inc. 201
Figure 3. The Structure of the CR2(CCP1-2):C3d Complex
(A) Comparison of the CR2:C3d binding interfaces in the 2001 (PDB 1GHQ,
Szakonyi et al., 2001) and 2011 (PDB 3OED, van den Elsen and Isenman, 2011)
CR2(CCP1-2):C3d cocrystal structures. Ribbon representations of the
essentially identical C3d molecules of the 2001 structure (yellow) and the 2011
structure (green) were superimposed in an orientationwhere one is looking into
the acidic pocket of the C3d molecule. The respective placements of the CR2
(CCP1-2) molecules in the 2001 and 2011 cocrystal structures are denoted by
the red and magenta ribbon diagrams, respectively. The gray spheres indicate
the respective positions of the two zinc atoms at the interface visualized in the
2001 structure.
(B) Depiction of the charge complementarity at the interface between the
positively charged side chains of CR2(CCP1-2) that point down toward the
acidic pocket on the concave surface of C3d. C3d is shown as a molecular
surface representation colored for electrostatic potential; red, negative; blue,
positive; and gray, neutral. The ribbon rendering of the CR2 domains is
semitransparent (adapted from van den Elsen and Isenman, 2011).
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patches on one face of the CR2(CCP1-2) molecule, as inferred
at that time from a homology model of these domains, the acidic
residue-lined depression of C3dwas proposed to be amajor site
of interaction with CR2(CCP1-2) (Nagar et al., 1998). Subse-
quently, an alanine scan mutational analysis of fully exposed
residues within the candidate site was published (Clemenza
and Isenman, 2000). This study not only provided support for
the hypothesis, but further identified two distinct subclusters of202 Immunity 37, August 24, 2012 ª2012 Elsevier Inc.residues located at opposite ends of the acidic pocket whose
mutation lead to profound defects in CR2 binding. Shortly there-
after, an alternative model for CR2 binding was suggested by
a cocrystal structure of CR2(CCP1-2):C3d that, as depicted by
the red CR2(CCP1-2) molecule in Figure 3A, shows no interac-
tionwithin themutationally defined contact areas on the concave
surface but rather shows CR2 binding via CCP2 only to a side
face of C3d (Szakonyi et al., 2001). From the outset, this structure
was discordant with biochemical data on several fronts,
including the strong indication that both CCP1 and CCP2 would
mediate the contact (Carel et al., 1990; Lowell et al., 1989). This
structure has not been supported by subsequent studies,
including one showing that the mutation of several basic resi-
dues in CCP1, which made no contact with C3d in the 2001 coc-
rystal structure, had a major effect on binding (Hannan et al.,
2005). Experiments showing that the concentration of zinc ion
used in the crystallization of the complex actually abolishes
CR2:C3d binding in solution (Isenman et al., 2010) have made
it likely that the 2001 structure represented a nonphysiologic
interaction promoted by the zinc in the crystallization buffer.
The recent characterization of secreted Staphylococcus
aureus virulence proteins extracellular fibrinogen-binding protein
(Efb) and Staphylococcal binder of immunoglobulin (Sbi), which
have constituent domains Efb-C and Sbi-IV, respectively, that,
like CR2, bind weakly to C3b but strongly to iC3b and C3dg
(Burman et al., 2008; Hammel et al., 2007) refocused attention
on the acidic residue-lined depression of C3d as being a major
contact site for CR2(CCP1-2). Both Sbi-IV (Burman et al.,
2008) and Efb-C (Ricklin et al., 2008) were shown to compete
with CR2 for binding to C3dg. Moreover, a cocrystal structure
of the Efb-C:C3d complex showed the three-helix bundle Efb-
Cmolecule binding on the concave face of C3d, and with several
of its helix 2 residues having side chains making specific contact
with residues in the acidic residue-lined depression of C3d.
These results prompted not only the use of the collection of
concave surface C3d mutants to map the interaction site of
Sbi-IV, which by this point had also been determined to have
a three-helix bundle fold (Upadhyay et al., 2008), but also reex-
amination using biophysical methodology, as compared to the
rosette assays of binding used in the 2000 study (Clemenza
and Isenman, 2000), of the CR2(CCP1-2) binding capacity of
an expanded collection of C3dg mutants. The results of these
studies reconfirmed the original findings regarding the impor-
tance of residues in the C3d acidic pocket for CR2 binding, as
well as showing that like Efb-C, this region of was also utilized
by Sbi-IV for its binding (Isenman et al., 2010).
Cocrystal Structure of the CR2(CCP1-2):C3d Complex
In crystallization conditions that avoid the use of nonphysiologic
salts, new diffracting cocrystals of the CR2(CCP1-2):C3d
complex have been obtained and yield the model depicted in
Figure 3A, in which the magenta-colored CR2(CCP1-2) is
the C3d-binding entity (van den Elsen and Isenman, 2011).
The V-shaped arrangement of the constituent domains of
CR2(CCP1-2) interact with the acidic pocket on the concave
surface of C3d, and there is excellent shape complementarity
of the surfaces. In the electrostatic surface potential rendering
of the C3dmolecule shown in Figure 3B, it can be seen how there
are several basic side chains of lysine and arginine residues of
Figure 4. Pathways for the Recognition of B
Cell Antigen in the Lymph Node
Processes depicted in the figure are as follows: (1)
Immune complexes (ICs), formed by the deposi-
tion of complement proteins (in this illustration,
C3d) and IgG on the surface of antigen, bind to
complement receptor 3 (CR3) on the surface of
subcapsular sinus macrophages (M). (2) Naive B
cells transport complement-coated ICs from
the subcapsular sinus to FDCs. (3) The ICs are
transferred in a complement receptor 2 (CR2)-
mediatedmechanism from the surface of the B cell
to the FDCs. (4) Cognate B cells capture small
antigen directly from the surface of FDCs, asso-
ciated with CR2 receptors (adapted from Gonza-
lez et al., 2011).
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acidic pocket in a manner that produces the charge comple-
mentarity expected from the long-known, ionic strength sensi-
tivity of this binding interaction. Many of the interactions
observed at the interface, be they charged, polar, or apolar,
conformed to mutagenesis data obtained previously (Clemenza
and Isenman, 2000; Hannan et al., 2005; Isenman et al., 2010) or
to mutagenesis experiments prompted by the new structure
(van den Elsen and Isenman, 2011). Finally, the substantially
overlapping contact areas on C3d observed among
CR2(CCP1-2), Efb-C, and Sbi-IV in their respective cocrystal
structures (Clark et al., 2011; Hammel et al., 2007; van den
Elsen and Isenman, 2011) readily explains the competition of
the Staphylococcal immune evasion molecules for CR2 binding
to C3d. Because of the nanomolar range affinity of Efb for C3d,
compared with the mM range affinity of Sbi for C3d (Hammel
et al., 2007; Upadhyay et al., 2008), the interaction of Efb with
any C3d molecules that become covalently attached to the
Staphylococcus aureus microbe may indeed be a physiologi-
cally relevant element through which this human pathogen
evades antibody-mediated adaptive immunity (Ricklin et al.,
2008).
Delivery of Antigen to Follicular Dendritic Cells
The findings that naive B cells are a major transporter of
complement-coated immune complexes in the B cell follicles
and that both uptake and transfer of the complexes to FDCs
are dependent for the most part on CR2 and C3d provide a third,
important pathway by which the complement system regulates
humoral immunity (Figure 4). Using multiphoton intravital
imaging in anesthetized mice, Phan et al. (2009) have found
that soluble immune complexes that form in the afferent
lymphatics and activate complement are captured by sinus-
lining macrophages, possibly via FcgR and complement CR3
(CD11b; CD18), and are shuttled to naive B cells in the under-
lying follicles. Complement-coated complexes are efficiently
transferred to follicular B cells in a CR2-dependent manner.
Although the model system used by Phan et al. relied on rabbit
IgG-phycoerythrin immune complexes to activate complement,
in a more physiologic setting of vaccination where preexistingantibody is likely to be absent, it seems probable that comple-
ment is activated within the lymphatics by other innate recogni-
tion proteins such as those noted above, i.e., natural IgM, lectin
proteins, or pentraxins like C-reactive protein. The finding that
the cell surface C-type lectin SIGN-R1, expressed by sinus-
lining macrophages, activates C1q and the classical pathway
of complement on binding of Streptococcus pneumonia (Kang
et al., 2006) provides another mechanism for formation of
C3d-tagged complexes. Whether this pathway leads to B cell
uptake of C3d-tagged bacteria has not been determined in
their model. Given that LN resident dendritic cells also express
SIGN-R1, and they have been reported to bind inactivated
influenza via SIGN-R1 and transport virus into the follicles
(Gonzalez et al., 2010), it is possible that they also transport
S. pneumonia into the B cell compartment. It will be interesting
to learn whether the resident DCs transfer C3-coated particles,
such as influenza or bacteria, to naive follicular B cells for the
actual delivery to FDCs or whether they deliver the complexes
directly.
The actual transfer of C3d-coated immune complexes from
naive B cells to FDCs has not been observed in vivo, but
CR2-deficient mice show impaired uptake of antigens (Roozen-
daal and Carroll, 2007). Although FDCs express FcgRII recep-
tors, they are not thought to be constitutively expressed and
only appear on activated FDCs (El Shikh et al., 2006). By
contrast, CR1 and CR2 are constitutively expressed on FDCs
(Roozendaal and Carroll, 2007). Thus, the initial transfer of
C3-coated complexes from naive B cells may induce activation
of FDCs, leading to expression of FcgRIIb that may subse-
quently modulate FDC activity (more discussion of FDC activa-
tion below).
FDCs Are a Source of B Cell Antigen
The clonal selection hypothesis proposes antigen is required for
positive selection and affinity maturation of B cells undergoing
somatic hypermutation within germinal centers (Rajewsky,
1996). Studies by Goodnow and colleagues have established
the importance of antigen in maintaining germinal centers
because blockade of antigen receptors led to ablation of the
germinal center response (Goodnow et al., 1995). Notably,Immunity 37, August 24, 2012 ª2012 Elsevier Inc. 203
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a soluble form of the CR2 receptor also leads to a rapid loss of
germinal centers (Fischer et al., 1998), suggesting that the overall
strength of signal of the B cell receptor is critical for B cell
survival. Early histology studies suggest that the major source
of antigen for germinal center responses is FDCs. Studies of
the LN and spleen of immunized mice traced labeled antigens
to dendritic-like cells that were later identified as FDCs (Hanna
and Szakal, 1968; Nossal et al., 1968). Surprisingly, it has been
observed that antigen is retained for long periods and in some
cases up to 1 year (Mandel et al., 1980). Thus, unlike macro-
phages and dendritic cells that degrade antigen after relatively
short periods, FDCs appear to retain antigens for extended
periods.
How these enigmatic stromal cells retain antigen for such
extensive periods but make it readily available to B cells is
unknown. Ultrastructural studies identify antigen retained as
membrane-coated bodies, also known as ICCOSOMES, that
are released and taken up by B cells within germinal center reac-
tions (Szakal et al., 1988; Szakal et al., 1989). Alternatively, it is
reported that FDCs retain electron dense antigens on their
surface as dense deposits that can take a filiform shape.
Despite the strong correlation between FDC retention of
antigen and efficient germinal center responses, actual observa-
tion of B cell acquisition of antigen from FDC in vivo has been
elusive. In a recent elegant study using intravital microscopy,
Suzuki et al. (2009) has observed direct uptake of antigen from
FDCs by cognate B cells. In their murine model, they adoptively
transferred immunoglobulin transgenic B cells specific for hen
egg lysozyme (Hel) into mice immunized with Hel conjugated
to phycoerythrin up to 9 days earlier. Interestingly, the cognate
B cells acquire not only specific antigen but also FDCmembrane
proteins CR2 and BP-3 (CD157, BST-1). It is known that B cells
can take up membrane antigens along with antigen from target
cells by a process referred to as trogocytosis. Although the study
didn’t report whether complement C3d and antibody were also
taken up, it is possible that the original C3d-coated immune
complexes are retained intact via CR2 on the FDC surface.
These findings are important because they establish that B cell
antigens are retained by FDCs and can be directly acquired
from the cell surface. These elegant results further suggest that
FDCs are a likely source of antigen for a primary B cell response.
FDCs Maintain Germinal Centers
In addition to their role in retention of antigen, FDCs are a major
source of the B cell chemoattractant CXCL-13, which is required
for migration of B cells into the follicles (Cyster et al., 2000). FDCs
differentiate from ubiquitous perivascular precursors (preFDCs)
that have been recently identified in an elegant report by Aguzzi
and colleagues (Krautler et al., 2012). Maturation of the precur-
sors requires signaling by members of the tumor necrosis factor
and lymphotoxin a-b family and presumably additional factors
within lymphoid tissues (Gonzalez et al., 1998; Katakai et al.,
2008; Koni et al., 1997). However, preFDCs can also differentiate
within nonlymphoid tissues and are often present in sites of
chronic inflammation as found in autoimmune disease and
infections.
In the presence of adjuvants and/or immune complexes, FDCs
become activated and increase release of B cell chemokines,204 Immunity 37, August 24, 2012 ª2012 Elsevier Inc.but also secrete the B cell-activating factor BAFF and proinflam-
matory cytokines such as IL-6 and IL-10 and upregulate integrins
ICAM-I and VCAM-1 (Garin et al., 2010;Wu et al., 2009). Whether
activation alters or promotes display of B cell antigen on their
surface is not known, but given the importance of antigen for
the duration of the germinal center response (3 weeks) the
latter seems most likely.
Earlier studies have demonstrated that treatment of mice with
a soluble form of the lymphotoxin receptor leads to transient
loss of mature FDCs and disruption of humoral responses
(Gommerman et al., 2002). In a definitive study, Wang et al.
(2011) have used a genetic approach to selectively ablate
FDCs in chimeric mice, demonstrating that FDCs are required
for maintenance of B cell follicles and germinal centers. Their
model system took advantage of CD21-specific Cre recombi-
nase transgenic mice crossed with a conditional diphtheria
toxin receptor (DTR) strain. Through construction of bone
marrow chimeras with WT bone marrow to reconstitute irradi-
ated CD21-DTR mice, DTR expression is limited primarily
to the CD21+ stromal population. Treatment of immunized
chimeric mice with diphtheria toxin leads to ablation of FDCs
within lymphoid tissues as expected. Characterization of the
mice within 48 hr of treatment reveals loss of germinal centers
and a disruption of the architecture of the B cell follicles.
A limitation of the model is that only transient responses
could be studied because the mice die within several days of
treatment with the toxin from an apparent involvement of the
central nervous system. An earlier study by Wyss-Coray has
identified expression of CD21 mRNA in the nervous system in
reporter mice, although the timing of expression is not known
(Moriyama et al., 2011). In the future, it will be important to deter-
mine the kinetics of CD21 expression within the developing
nervous system and identify potential participation in peripheral
immunity.
FDC and Autoimmunity
Not all antigens acquired by FDCs lead to immune responses.
Using an intricate maternal self-antigen transgenic model in
which ovalbumin (OVA) expression is limited to the placentae,
McCloskey et al. (2011) has found that self-antigen released at
parturition accumulates on FDCs located in draining LNs and
its uptake is enhanced by classical pathway complement. To
test for T cell response to the self-antigen retained by FDCs,
they adoptively transferred carboxyfluorescein diacetate succi-
nimidyl ester (CFSE)- labeled CD8+ OVA-specific T cells (OT-I)
several weeks after parturition, at a time when it was predicted
that antigen would be cleared from the host with the exception
of antigen retained by FDCs. Analysis of harvested LNs at the
optimal period has determined that antigen-specific CD8+
T cells were not activated and appeared to be tolerized by
resident DC sampling antigen from the FDCs. For a control,
McCloskey et al. demonstrated that when OT-1 cells were
adoptively transferred before immunization with OVA immune
complexes and adjuvant, there was a robust response; by
contrast, adoptive transfer several weeks later results in toler-
ance. Their results are important for several reasons: First, they
suggest that resident DCs periodically sample both self- and
foreign antigen displayed by FDCs. Second, DC sampling
of antigen from FDCs results in a tolerogenic rather than
Immunity
Reviewactivation signal for CD8+ T cells under the conditions defined in
this study.Cr2:C3d As a Target for Autoimmunity
Like development of a conventional B cell memory response
after vaccination with foreign antigen, autoreactive B cells
may undergo a similar pathway of differentiation into isotype-
switched memory and effector cells. There is growing evidence
that spontaneous germinal center formation may contribute
to autoimmunity in mice and humans (Cappione et al., 2005;
Vinuesa et al., 2009). Moreover, ectopic germinal centers, i.e.,
germinal centers formed in nonlymphoid tissues, are a hallmark
of chronic autoimmunity such as in arthritis (Grammer et al.,
2003). Therefore, it seems plausible that differentiating auto-
reactive B cells may have a similar requirement for coreceptor
engagement of C3d along with B cell receptor binding of self-
antigen. Thus, blockade of the CR2 coreceptor could provide
a transient therapy to eliminate autoimmune germinal centers
without imposing immune suppression to the naive B cell
repertoire.
The details of the interface revealed from the cocrystal struc-
ture of CR2:C3d may allow one to design a compound that
would, for example, interfere with the trapping of C3d-tagged
self-antigens by CR2 on FDCs, thereby potentially downmodu-
lating or ‘‘tune down’’ antibody-mediated autoimmunity. It is
known from mutagenesis data that removing even a part of the
contact interface can lead to a major binding defect and so
with therapeutic target surfaces available on both sides of the
interface, sometimes involving contiguous stretches of amino
acid sequence, a peptide-basedmimetic approach to the design
of such an antagonist should be within the realm of feasibility.
Therefore, it will be important in future experiments to determine
whether autoreactive B cells have a similar requirement as
conventional B cells for CR2 signal in survival within germinal
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